Exenatide vs Lixisenatide
Exenatide (GLP-1 receptor agonist) and Lixisenatide (GLP-1 receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Page updated 2026-09-20. Latest review of a source entry: 2026-09-20. Editorial method.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Exenatide | Lixisenatide |
|---|---|---|
| Compound class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | Not documented | Not documented |
| Molecular weight | Not documented | Not documented |
| Half-life | Not documented | Not documented |
| Origin | The DURATION-1 trial compared two exenatide formulations over 30 weeks in 295 adults with type 2 diabetes. This entry adds a formulation-focused comparator to the GLP-1 library. | ELIXA examined lixisenatide in people with type 2 diabetes who had recently experienced an acute coronary event. It offers an important example of why cardiovascular findings cannot be assumed to apply to every GLP-1 compound. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Exenatide works
Its GLP-1 receptor activity provides the mechanistic context for studies of glucose regulation.
How Lixisenatide works
Lixisenatide engages the GLP-1 receptor; ELIXA evaluated clinical outcomes rather than establishing a new receptor mechanism.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Described in identical terms for both
Exenatide
Lixisenatide
What sets each apart
Exenatide
A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.
Lixisenatide
The trial did not demonstrate a significant change in major cardiovascular events compared with placebo. This is different from demonstrating cardiovascular benefit.
Frequently asked questions
What is the evidence context for Exenatide?
A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
What is the evidence context for Lixisenatide?
The trial did not demonstrate a significant change in major cardiovascular events compared with placebo. This is different from demonstrating cardiovascular benefit.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.
Linked publications
Publications recorded on each compound's profile, including original studies and reviews. These are background sources for the separate compounds; listing them together does not establish a direct comparison, a combination study, or equivalent evidence. Read the study design and limitations before interpreting a finding.